Evidence map›Paper›PMID 40694497›Full record

ArticleeLife2025

Metastatic small cell lung cancer arises from TP53/RB1-deficient and MYC overproduction hESC-derived PNECs.

Huanhuan Joyce Chen, Eric E Gardner, Yajas Shah, Kui Zhang, Abhimanyu Thakur, Chen Zhang, Olivier Elemento, Harold Varmus

Abstract read
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Huanhuan Joyce Chen *Meyer Cancer Center, Weill Cornell Medicine, New York, United States.ORCID https://orcid.org/0000-0002-1446-7184
Eric E Gardner *Meyer Cancer Center, Weill Cornell Medicine, New York, United States.ORCID https://orcid.org/0000-0002-1552-2675
Yajas ShahCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, United States.
Kui ZhangThe Pritzker School of Molecular Engineering, The University of Chicago, Chicago, United States.
Abhimanyu ThakurThe Pritzker School of Molecular Engineering, The University of Chicago, Chicago, United States.ORCID https://orcid.org/0000-0002-0846-0998
Chen ZhangDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, United States.
Olivier ElementoCaryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, United States.
Harold VarmusMeyer Cancer Center, Weill Cornell Medicine, New York, United States.

Funding

Studies of the initiation and progression of small cell lung cancer using cells derived by differentiation from human pluripotent stem cellsU01CA224326 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI VARMUS, HAROLD E. · 2018 to 2022
$2.4M
Unraveling Metastasis Drivers in Small Cell Lung Cancer via Human Pluripotent Stem Cell-Based ApproachR21CA299377 · NCI · UNIVERSITY OF CHICAGO · PI Joyce Huanhuan Chen · 2025 to 2026
$422k
Department of Defense Education Activity LC160136Department of Defense Education Activity RA220012Lung Cancer Research Foundation Pilot ProjectNCI NIH HHS R21 CA299377NCI NIH HHS U01CA224326NIH HHS 4R00CA226353
6 · The paper itself

Abstract

We previously described our initial efforts to develop a model for small cell lung cancer (SCLC) derived from human embryonic stem cells (hESCs) that were differentiated to form pulmonary neuroendocrine cells (PNECs), a putative cell of origin for neuroendocrine-positive SCLC. Although reduced expression of the tumor suppressor genes TP53 and RB1 allowed the induced PNECs to form subcutaneous growths in immune-deficient mice, the tumors did not display the aggressive characteristics of SCLC seen in human patients. Here, we report that the additional, doxycycline-regulated expression of a transgene encoding wild-type or mutant MYC protein promotes rapid growth, invasion, and metastasis of these hESC-derived cells after injection into the renal capsule. Similar to others, we find that the addition of MYC encourages the formation of the SCLC-N subtype, marked by high levels of NEUROD1 RNA. Using paired primary and metastatic samples for RNA-sequencing, we observe that the subtype of SCLC does not change upon metastatic spread and that production of NEUROD1 is maintained. We also describe histological features of these malignant, SCLC-like tumors derived from hESCs and discuss potential uses of this model in efforts to control and better understand this recalcitrant neoplasm.

Indexed as

Human Embryonic Stem CellsLung NeoplasmsNeuroendocrine CellsProto-Oncogene Proteins c-mycRetinoblastoma Binding ProteinsSmall Cell Lung CarcinomaTumor Suppressor Protein p53Ubiquitin-Protein LigasesAnimalsBasic Helix-Loop-Helix ProteinsCell DifferentiationHumansMiceNeoplasm MetastasisBasic Helix-Loop-Helix ProteinsMYC protein, humanNEUROD1 protein, humanProto-Oncogene Proteins c-mycRB1 protein, humanRetinoblastoma Binding ProteinsTP53 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein Ligasescancer biologyhESClung cancermouseSCLC

Identifiers

PMID40694497
PMCPMC12283072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.